News items related to: Medicine Equality Now!
-
Empowering Africa’s Pharmaceutical Future: Local Manufacturing and IP Reform as Game-Changers
The African pharmaceutical market is on the rise, with its value soaring to $25 billion in 2022 and projected to...
-
ITPC-EECA Challenges Patents on core DR-TB Drug Pretomanid, Urging Eurasian Patent Office to Protect Access
According to WHO, 400,000 people developed DR-TB in 2023, yet only 44% (175, 923) of them were treated for it....
-
MMA Partner VNP+ Opposes Patent Application Which Would Limit Access to Long-Acting Cabotegravir
Vietnam’s Network of People Living With HIV (VNP+), a Make Medicines Affordable (MMA) partner, is working to improve access to, and affordability...
-
Thai HIV Advocacy Group Challenges Gilead’s and Janssen’s Patent Extension Bid, Citing Evergreening Tactics
The Thai Network of People Living with HIV/AIDS (TNP+) filed an opposition to a patent application filed by the U.S.-based pharmaceutical giant...
-
People’s Resolution: A Roadmap to Protect the Right to Life in a Failed Multilateral Order
We, as members of communities, civil society and activists affected by epidemics, call for a plan of action to end...
-
J & J’s Deal With the Global Drug Facility Disguises the Continued Issue with Access to Bedaquiline to Treat Drug-Resistant Tuberculosis
“This deal is big step backwards for global public health – it allows J & J to keep selling higher-priced...
-
The pandemic is declared finished, but the fight for access never stops
MMA consortium members from Argentina, Brazil, Thailand and EECA region, took action to secure access to molnupiravir. In Argentina, the...
-
Being ahead of the curve: access to Delamanid in Thailand
MMA’s consortium partner, the Thai Network of People Living with HIV/AIDS (TNP+), has filed a third-party observation on a patent...
-
Civil Society Organizations in Brazil fight for better access to Dolutegravir
Brazilian Interdisciplinary AIDS Association (ABIA), along with the Working Group on Intellectual Property (GTPI) of the Brazilian Network for the...
-
Paxlovid in the post pandemic world
The World Health Organization (WHO) recently declared that COVID-19 is “…now an established and ongoing health issue which no longer...
-
Patent-free, low-cost vaccines highly protective against severe COVID
A new analysis of 390,459 participants assessing 14 different COVID-19 vaccines has identified no significant difference in efficacy against both symptomatic and severe...
-
TNP+ opposes patent claims on Lenacapavir
TNP+, MMA’s partner in Thailand, has filled an opposition against Markush patent claims on lenacapavir, a new, long-acting antiretroviral drug,...